Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzthiazide is a thiazide diuretic used primarily for the treatment of hypertension and edema. It acts by inhibiting the sodium-chloride symporter (Na⁺/Cl⁻ cotransporter) in the distal convoluted tubule of the kidney, leading to increased excretion of sodium and chloride ions. This results in enhanced water loss (diuresis), reduction in blood volume, and subsequently lower blood pressure. Benzthiazide also causes potassium loss via increased exchange with sodium and can increase serum uric acid levels. Its antihypertensive effect may also involve vasodilation through activation of large-conductance calcium-activated potassium channels in vascular smooth muscle and inhibition of carbonic anhydrases within vascular tissue. The drug was developed by Pfizer and marketed under several brand names but is no longer available in some markets such as the United States[1][2][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Benzthiazide.